Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03271372 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Avelumab in Merkel Cell Cancer
A Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8, sponsored by University of Washington.
- Active
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 9
- Study locations
NCT03271372: Active Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8, sponsored by University of Washington.
NCT03271372 is a Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8 that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 101 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03271372, a Phase 3 study of Stage III Merkel Cell Carcinoma AJCC v8 and Stage IIIB Merkel Cell Carcinoma AJCC v8, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 9
- Study locations
Study Summary
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
The Kaplan-Meier technique will be used to obtain estimates.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Avelumab
- OTHER Peripheral Blood Collection
Study Locations (9)
California
- University of California Irvine Chao Family Comprehensive Cancer Center - Orange
Colorado
- University of Colorado Cancer Center University of Colorado Anschutz Medical Campus - Aurora
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- University of North Carolina Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2029-02-18 |
| Phase | Phase 3 |
What the registry record for NCT03271372 still lists
NCT03271372 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Stage III Merkel Cell Carcinoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03271372 lists 9 locations in 9 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT03271372 about?
NCT03271372 is a clinical study titled "Adjuvant Avelumab in Merkel Cell Cancer". This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack th...
What is the current status of trial NCT03271372?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2017-12-19. Estimated completion is 2029-02-18.
What conditions does trial NCT03271372 study?
This clinical trial studies the following conditions: Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8.
What interventions are being tested in trial NCT03271372?
The interventions under investigation include: Placebo (OTHER), Avelumab (DRUG), Peripheral Blood Collection (OTHER).
Who is sponsoring clinical trial NCT03271372?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03271372 being conducted?
This trial has 9 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03271372's enrollment target sits among peer trials
101 1681st of 2000 higher than 320 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI